NCT05237622

Brief Summary

Although there is a widespread use of HighFlow therapy around the world, there is still uncertainty about the most appropriate initial HighFlow level after nasal continuous positive airway pressure therapy. Higher levels might produce excessive and harmful intra-alveolar pressures exceeding those reached during nasal continuous positive airway pressure therapy. Low levels may not generate sufficient distending pressures, which may result in a loss of functional residual capacity and an increased risk of respiratory failure. Therefore, the aim of this study is to assess the effect of different HighFlow levels on the functional residual capacity and to compare these findings to the functional residual capacity during nasal continuous positive airway pressure therapy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Feb 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 2, 2022

Completed
12 days until next milestone

First Posted

Study publicly available on registry

February 14, 2022

Completed
5 days until next milestone

Study Start

First participant enrolled

February 19, 2022

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 13, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 13, 2023

Completed
Last Updated

July 9, 2024

Status Verified

July 1, 2024

Enrollment Period

11 months

First QC Date

February 2, 2022

Last Update Submit

July 4, 2024

Conditions

Keywords

Non-invasive respiratory supportHighFlowcontinuous positive airway pressurefunctional residual capacity

Outcome Measures

Primary Outcomes (1)

  • Change in global end-expiratory lung impedance (EELI) during the weaning procedure from nasal continuous positive airway pressure (nCPAP) to HighFlow (HF)

    Change in global EELI over time using electrical impedance tomography (EIT)

    230-minute recording period per patient, 30 minutes on each HF level

Secondary Outcomes (11)

  • Change in mean respiratory rate (RR) during the weaning procedure from nasal continuous positive airway pressure (nCPAP) to HighFlow (HF)

    230-minute recording period per patient, 30 minutes on each HF level

  • Change in regional end-expiratory lung impedance (EELI) during the weaning procedure from nasal continuous positive airway pressure (nCPAP) to HighFlow (HF)

    230-minute recording period per patient, 30 minutes on each HF level

  • Change in mean minute volume during the weaning procedure from nasal continuous positive airway pressure (nCPAP) to HighFlow (HF)

    230-minute recording period per patient, 30 minutes on each HF level

  • Change in mean ventilation distribution during the weaning procedure from nasal continuous positive airway pressure (nCPAP) to HighFlow (HF)

    230-minute recording period per patient, 30 minutes on each HF level

  • Change in mean silent spaces during the weaning procedure from nasal continuous positive airway pressure (nCPAP) to HighFlow (HF)

    230-minute recording period per patient, 30 minutes on each HF level

  • +6 more secondary outcomes

Study Arms (1)

High Flow

OTHER

Standard HighFlow therapy after weaning from continuous positive airway pressure therapy will be applied on different flow levels. Starting with a flow level of 8l/min, the flow-rates will be changed every 30 minutes subsequently from 8-6-4-2-4-6-8 l/min. Meanwhile, data lung volume changes will be measured using electrical impedance tomography.

Device: High Flow

Interventions

High FlowDEVICE

Standard HighFlow therapy after weaning from continuous positive airway pressure therapy will be applied on different flow levels. Starting with a flow level of 8l/min, the flow-rates will be changed every 30 minutes subsequently from 8-6-4-2-4-6-8 l/min. Meanwhile, data on lung volume changes will be measured using electrical impedance tomography.

High Flow

Eligibility Criteria

Age73 Hours+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Written Informed Consent by one or both parents or legal guardians as documented by signature
  • weeks postmenstrual age
  • Respiratory support with nCPAP PEEP 5mbar and FiO2 \< 0.30
  • \> 72 hours old

You may not qualify if:

  • Inability of the parents to understand the study concept or procedures due to cognitive or linguistic reasons
  • Congenital malformations adversely affecting lung aeration or pulmonary perfusion (e.g. congenital heart or lung defects)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Newborn Research, Department of Neonatology, University Hospital Zurich

Zurich, 8091, Switzerland

Location

Related Publications (3)

  • Collins CL, Holberton JR, Barfield C, Davis PG. A randomized controlled trial to compare heated humidified high-flow nasal cannulae with nasal continuous positive airway pressure postextubation in premature infants. J Pediatr. 2013 May;162(5):949-54.e1. doi: 10.1016/j.jpeds.2012.11.016. Epub 2012 Dec 20.

    PMID: 23260098BACKGROUND
  • Frerichs I, Amato MB, van Kaam AH, Tingay DG, Zhao Z, Grychtol B, Bodenstein M, Gagnon H, Bohm SH, Teschner E, Stenqvist O, Mauri T, Torsani V, Camporota L, Schibler A, Wolf GK, Gommers D, Leonhardt S, Adler A; TREND study group. Chest electrical impedance tomography examination, data analysis, terminology, clinical use and recommendations: consensus statement of the TRanslational EIT developmeNt stuDy group. Thorax. 2017 Jan;72(1):83-93. doi: 10.1136/thoraxjnl-2016-208357. Epub 2016 Sep 5.

    PMID: 27596161BACKGROUND
  • van der Burg PS, Miedema M, de Jongh FH, Frerichs I, van Kaam AH. Cross-sectional changes in lung volume measured by electrical impedance tomography are representative for the whole lung in ventilated preterm infants. Crit Care Med. 2014 Jun;42(6):1524-30. doi: 10.1097/CCM.0000000000000230.

    PMID: 24561568BACKGROUND

MeSH Terms

Conditions

Infant, Premature, DiseasesRespiratory Distress Syndrome

Condition Hierarchy (Ancestors)

Infant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesLung DiseasesRespiratory Tract DiseasesRespiration Disorders

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 2, 2022

First Posted

February 14, 2022

Study Start

February 19, 2022

Primary Completion

January 13, 2023

Study Completion

January 13, 2023

Last Updated

July 9, 2024

Record last verified: 2024-07

Locations